SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalanche is a high throughput smart contract blockchain platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche (AVAX) is trending amid discussions of significant institutional interest, fueled by its potential for Real World Asset (RWA) tokenization and a new ETF filing that includes staking. Despite some investor frustration over recent price action, the community remains highly engaged, emphasizing AVAX's strong fundamentals, unique subnet architecture, and deflationary tokenomics as key drivers for future growth and adoption. The ongoing debate revolves around the disconnect between these bullish developments and current market performance.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is experiencing renewed excitement driven by broader altcoin season narratives, with the community rallying around the potential for a "zero drop". Despite recent volatility, many holders are accumulating, viewing current price action as a buying opportunity for the popular meme coin.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is trending amid significant catalysts aimed at boosting its legitimacy and reducing supply, notably the upcoming 1 trillion token burn as the community nears 1 million holders. The recent launch of its first ETP on the SIX Swiss Exchange and new utility like the "kill-to-earn" Bonk Arena are fueling community discussions of a potential major rebound and an "alt/meme season" within the Solana ecosystem.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

SHIB is currently trending amid highly polarized community sentiment, with many debating if it's a "bull trap" or a prime "buy the dip" opportunity at perceived low prices. Discussions are rife with calls for a significant "squeeze" and the broader "alt season" narrative, even as others express skepticism and label it a "scam" or a "dead coin." The community remains deeply divided on its immediate future, reflecting ongoing volatility and uncertainty in the meme coin space.

Memecoin on Injective taken over by the community.

Nonja

NONJA CRYPTO is trending as its community actively positions it as a high-leverage play on the Injective ecosystem, anticipating significant upside with Injective's robust fundamentals and upcoming market catalysts. Enthusiasts highlight NONJA's strong community, high burned liquidity, and successful NFT collections, believing it to be a resilient and undervalued gem poised for substantial growth.

English version Introducing SWFTCoin (SWFTC) $SWFTC: Powering SWFT Blockchain and AI Services (SWFTGPT)  SwftCoin ($SWFTC) is the native utility token driving SWFT Blockchain's AI-powered ecosystem, SWFTGPT, and the first ever AI token featured on Coinbase. SWFTGPT is also the first domain-specific LLM for crypto.  SwftCoin key features include: 50% Reduced Transaction Fees: Lower costs on all transactions. AI Service Payments: Use $SWFTC to access SWFTGPT. Tools include expert market analysis,  predictions, and intelligent trading solutions.  Membership Benefits: Unlock premium features and AI agent services within SWFTGPT. AI-Powered Swaps: Enable precise, fast cross-chain transactions and analytics. SWFT Blockchain combines AI innovation with blockchain infrastructure, simplifying crypto trading while enhancing functionality through $SWFTC.   Chinese version $SWFTC：驱动 SWFT Blockchain 和 AI 服务（SWFTGPT） SwftCoin ($SWFTC) 是 SWFT Blockchain 的原生实用代币，为其 AI 驱动的生态系统 SWFTGPT 提供支持，同时也是 Coinbase 上首个 AI 代币。SWFTGPT 也是首个专注于加密领域的特定领域大型语言模型 (LLM)。 SwftCoin 的主要功能包括： 1、50% 交易费减免：降低所有交易成本。 2、AI 服务支付：使用 $SWFTC 访问 SWFTGPT 工具，包括专家市场分析、预测以及智能交易解决方案。 3、会员权益：解锁 SWFTGPT 的高级功能和 AI 代理服务。 4、AI 驱动的闪兑：实现精准快速的跨链交易和数据分析。 SWFT Blockchain 将 AI 创新与区块链基础设施结合，通过 $SWFTC 简化加密交易，并提升其功能性。

SwftCoin

SwftCoin (SWFTC) is trending with increased community engagement, driven by buzz surrounding potential new major exchange listings, notably Coinbase, and a significant surge in trading volume. The community is actively discussing its fully diluted supply, AI-integrated exchange, and cross-chain bridging technology, anticipating substantial "altseason" gains and its pivotal role in the evolving multi-chain ecosystem.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending due to recent announcements regarding the expansion of its anticoagulant drug pipeline through new acquisitions, including a 12-LOX inhibitor for heparin-induced thrombocytopenia (HIT), and strategic collaborations for its tecarfarin program. This has sparked a divided community, with many investors anticipating significant upside from its low float and regulatory designations, while a vocal group expresses strong skepticism, citing concerns over potential dilution and the company's financial stability. The ongoing conversation centers on whether these pipeline advancements will solidify CVKD's position as a multi-asset biotech.

|The Artificial Superintelligence (ASI) Alliance is the world’s largest open-source initiative dedicated to decentralized Artificial General Intelligence (AGI). Formed in April 2024, the ASI Alliance unites SingularityNET, Fetch.ai, and Ocean Protocol, with CUDOS joining as a network member shortly after. The ASI Alliance was established through a community-approved tokenomic merger—combining $AGIX, $FET, and $OCEAN into a single token: $FET. This unified token underpins a collaborative framework designed to scale open-source AI and stand as the largest open-sourced, independent entity in AI research and development. The Alliance is committed to accelerating the advancement of decentralized Artificial General Intelligence (AGI) and, ultimately, Artificial Superintelligence (ASI). It provides a robust, open-source innovation stack, empowering developers, enterprises, and researchers globally to build ethical, scalable, and groundbreaking AI solutions. This ensures that advanced intelligence remains a shared, accessible resource, fostering innovation beyond centralized systems and promoting a future where AI benefits all.

Fetch.ai

Fetch.ai is buzzing with renewed optimism following its partnership with Google Cloud for AI agent development, alongside growing real-world adoption exemplified by new enterprise deals. The community is actively discussing FET as an undervalued asset, anticipating substantial growth as the decentralized AI and machine economy narratives gain traction. Many investors view current price levels as a key accumulation opportunity, confident in its strategic positioning within the evolving AI landscape.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance (AERO) is a trending topic, driven by its recent listing on Robinhood and its pivotal role as the leading liquidity hub on the rapidly expanding Base network. The community is buzzing about its robust revenue generation, strategic tokenomics, and an anticipated merger with Velodrome that aims to establish a powerful cross-chain DeFi ecosystem. Despite broader market uncertainties, many view AERO as a fundamental player positioned for significant growth.

EHang Holdings Ltd. engages in the provision of aerial vehicle technology platform company. It also provides unmanned aerial vehicle (UAV) systems and solutions: air mobility (including human transportation and logistics), smart city management, and aerial media solutions. The firm operates through the following geographical segments: P.R.C., West Asia, East Asia, South America, Europe, and Other. The company was founded by Huazhi Hu and Yifang Derrick Xiong in December 2014 and is headquartered in Guangzhou, China.

EHang Holdings Ltd - ADR

EHang Holdings

EHang Holdings is trending amid a split investor sentiment following a significant reduction in its full-year revenue guidance and a subsequent analyst downgrade. While some investors express frustration over the stock's performance and management's consistency, others remain bullish, pointing to the company's continuous progress in autonomous eVTOL technology and upcoming commercial operational launches in regions like Thailand and Saudi Arabia.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<h3>Agreement includes minimum annual order commitments totalling approximately USD $1.3 million</h3>MELBOURNE, Australia, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science based innovator in gel based oral delivery technologies, today announced that it has entered into a three year sales agreement with Shenzhen Mana Health Management Co. Ltd. (“Mana”) under which Mana will distribute consumer nutritional products within China using Gelteq’s proprietary gel formulation. The agreement represents a significant step forward in expanding Gelteq’s nutritional product portfolio in China.Mana is a well-established distributor of healthcare and wellness products in China with a strong digital presence and a network of offline retail sales channels. This infrastructure provides an existing platform to introduce Gelteq’s nutritional formulations to a new and broad consumer base across the country.Under the agreement, Mana will promote, market, and sell a nutritional formulation primarily focused on sugar lowering across China through its multichannel healthcare network. The agreement also includes minimum annual order volumes during its three-year term which Gelteq expects to derive a minimum revenue of approximately USD $1.3 million during the term of the agreement.The agreement accelerates Gelteq’s strategy to expand its proprietary nutritional formulations in China, one of the world’s largest and fastest growing wellness and functional nutrition markets. The agreement also establishes a pathway to introduce additional nutritional products that incorporate Gelteq’s proprietary technology.“Our agreement with Mana Health represents a significant milestone in expanding nutritional products featuring Gelteq’s technology in China,” said Nathan Givoni, Chief Executive Officer of Gelteq. “By securing multi-year minimum commitments from distributors such as Mana, we seek to generate predictable revenue and advance the adoption of our platform in one of the most strategically important markets for nutritional products globally.”The agreement builds upon the recent launch of Gelteq’s sports performance range across Asia and reflects increased demand for Gelteq’s innovative gel based technology. The Company’s expanding presence in Asia demonstrates both market readiness and consumer appetite for scientifically developed delivery formats that enhance convenience, taste, and functionality.“The momentum we are seeing across Asia highlights the versatility of our gel platform and the readiness of our regional partners to distribute our science driven solutions,” Mr. Givoni said. “We are actively pursuing additional partnerships of a similar nature in the near term.”About Gelteq Ltd.Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a biotechnology company that has developed a novel drug delivery platform in an ingestible gel form. Gelteq specializes in the formulation, development and manufacturing of gel products for licensed partners across pharmaceutical, consumer health and animal health markets. The proprietary formulation technology aims to address challenges associated with conventional drug and nutrient delivery by enhancing bioavailability, improving patient compliance, and enabling precise dosing. For more information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=tBon1Mk31lSV1X44QsCUylVsZfOkctA_mNtrMtNPGzSYJrwsiPvSN-4INpzpMW0wLJBmz2S5QLpoj-Y2d-Y4_w==">www.gelteq.com</a>.Gelteq Contact: Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 mkreps@darrowir.comForward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 17, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/NewsRoom/AttachmentNg/178e1a9c-f21e-4691-add7-b1398d96f7a6"><img style="height:auto;" src="https://ml.globenewswire.com/media/178e1a9c-f21e-4691-add7-b1398d96f7a6/small/gelteq-jpg.jpg" alt="Primary Logo" width="150" height="22"></a>Source: Gelteq LimitedReleased December 9, 2025Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq Signs Three Year Sales Agreement with Shenzhen Mana Health Management Co. Strengthening Gelteq’s Nutritional Product Expansion into China

Gelteq signed a three-year agreement with Shenzhen Mana Health Management to distribute its sugar-lowering nutritional products in China, guaranteeing approximately $1.3 million in minimum revenue.

Others

MELBOURNE, Australia, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based developer of advanced gel-based oral delivery systems, today announced preclinical findings demonstrating the effectiveness, flexibility, and safety profile of its proprietary gel platform. The results address a major challenge in pharmaceutical development and demonstrate that Gelteq’s technology can enhance the oral delivery of oil-soluble and poorly soluble drugs.Across two complementary preclinical studies, the results showed a more rapid absorption of an oil soluble compound in Gelteq’s gel base compared to an existing FDA approved reference product, with a 300 percent increase in bioavailability across the first hour. High bioavailability in the first hour is critical for rapid onset of action.Further results demonstrated that the oil soluble compound wasn’t just more rapidly absorbed in Gelteq’s gel base, but the overall absorption was also improved. Over 24 hours, the absorption was improved by more than 20 percent overall compared to an existing FDA approved reference product. These findings further illustrate that Gelteq’s gel matrix can support the delivery of lipophilic compounds whilst moderating the need for high levels of emulsifiers.The study results also demonstrate that Gelteq’s platform enables controlled movement through the digestive system, targeted release, and effective absorption while maintaining full clearance of both the active pharmaceutical ingredients (API) and the gel material itself.The GI transit evaluation demonstrated that the gel disperses the active ingredient uniformly along the small intestine. This extended distribution behaviour supports improved absorption through both mucoadhesive interactions and the presentation of the drug across a larger intestinal surface area.The studies also showed that the gel can be formulated to allow efficient transit and rapid early absorption of the API. The gel’s structural matrix dispersed and cleared effectively to the large intestine, reinforcing the platform’s safety and compatibility with oral administration.These combined findings highlight Gelteq’s potential to provide a new and more versatile alternative to existing oral delivery approaches for oil-soluble and poorly soluble drugs.With more than 40 percent of approved drugs and up to 90 percent of developmental candidates affected by poor solubility and bioavailability, the industry continues to invest billions of dollars1 annually in new technologies to overcome these issues. Gelteq’s platform offers a streamlined solution that may reduce developmental burdens, enhance bioavailability, and open pathways to revive previously shelved or challenging molecules.Therapeutic areas most likely to benefit from Gelteq’s gel-based delivery system include neurology, inflammation and pain management, hormonal therapies, cardiovascular medicine, nutraceuticals, weight management, oncology and veterinary health - categories where lipid-based or poorly soluble APIs are common and where improved absorption could meaningfully enhance clinical performance.By enabling more consistent absorption, targeted delivery, reduced excipient reliance, and strong safety characteristics, the gel-based delivery system positions Gelteq as a valuable development partner for pharmaceutical and nutraceutical companies seeking to reformulate existing assets or address complex formulation challenges in their pipelines.About Gelteq Ltd.Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a biotechnology company that has developed a novel drug delivery platform in an ingestible gel form. Gelteq specializes in the formulation, development and manufacturing of gel products for licensed partners across pharmaceutical, consumer health and animal health markets. The proprietary formulation technology aims to address challenges associated with conventional drug and nutrient delivery by enhancing bioavailability, improving patient compliance, and enabling precise dosing. For more information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=8TzpuxlNIZnf90MC0gt__SjBKV07HnilBr_4YjEopptBEfiLyv9wJKW-5OUbN7TXIYfw0WSX-OqI0wqEzv-2HQ==">www.gelteq.com</a>.Gelteq Contact: Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 mkreps@darrowir.comForward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 17, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof._________________________ 1 Solubility Enhancement Excipients Market Size 2025-2032<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/NewsRoom/AttachmentNg/178e1a9c-f21e-4691-add7-b1398d96f7a6"><img style="height:auto;" src="https://ml.globenewswire.com/media/178e1a9c-f21e-4691-add7-b1398d96f7a6/small/gelteq-jpg.jpg" alt="Primary Logo" width="150" height="22"></a>Source: Gelteq LimitedReleased December 5, 2025Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based Platform

Gelteq announced preclinical results demonstrating its proprietary gel platform significantly improved the absorption and bioavailability of poorly soluble drugs.

MELBOURNE, Australia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (Nasdaq: GELS) (“Gelteq”) today announced that Nathan Givoni, its Chief Executive Officer, will present at the&nbsp;Q4 Investor Summit Virtual on December 9, 2025, where he will share updates on Gelteq’s growth strategy, market positioning, and upcoming catalysts. The Investor Summit is an exclusive virtual event connecting investors with disruptive small and microcap companies. This quarter’s event highlights MicroCap companies with compelling value propositions and near-term growth drivers, offering investors a focused platform for discovery.Mr. Givoni will be presenting on December 9 at 4:00 PM ET, together with hosting one-on-one meetings with Institutional and High Net Worth (HNW) investors on December 10th. To request a one-on-one meeting, please reach out to the conference contact or Gelteq investor relations, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=auqwme3YdpYiaBjxXGSAWDOcJPN_1fxIx_B_lJO2Ot1jQ93GVjfRsma0DFbuOrsbln1KcIa5u-foTiXxN1emquUFqcWnPDmAQHbPm7PQPG4=">mkreps@darrowir.com</a>.Event Details:<ul><li>Event: Q4 Investor Summit</li><li>Presentation Date &amp; Time: December 9 | 4:00 PM ET</li><li>Request Access: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investorsummitgroup.com/">https://investorsummitgroup.com/</a>&nbsp;&nbsp;</li><li>Conference Contact: For more information, please contact: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:fred@investorsummitgroup.com">fred@investorsummitgroup.com</a></li></ul>About Gelteq Ltd. Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company dedicated to developing and commercialising gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing. For more information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=l1iFXs67cLJoJ6QWLjqPxC7Jfn9AwDiwSZM4VDbHDQBTCOryjUdIVFugvfQpltStl5L8j7NSuSGTKmuoZ0GqeQ==">www.gelteq.com</a>.Gelteq Contact: Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=auqwme3YdpYiaBjxXGSAWGoTfcdGe6pByXXUHGMOlq9DGCxmWi1tAwlsChGi4FKBjiTkRo98Jt_YcGboxWlDTkdgw1O-ohPRL-Moea_0OT0=">mkreps@darrowir.com</a>Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 17, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/NewsRoom/AttachmentNg/178e1a9c-f21e-4691-add7-b1398d96f7a6"><img style="height:auto;" src="https://ml.globenewswire.com/media/178e1a9c-f21e-4691-add7-b1398d96f7a6/small/gelteq-jpg.jpg" alt="Primary Logo" width="150" height="22"></a>Source: Gelteq LimitedReleased December 2, 2025Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq to Present at Investor Summit Virtual on December 9, 2025

Gelteq Limited CEO, Nathan Givoni, is scheduled to present updates on the company's growth strategy and market positioning at the Q4 Investor Summit Virtual on December 9, 2025.

MELBOURNE, Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced positive preclinical results showing its proprietary gel formulation achieved substantially higher bioavailability than a leading on-market reference antihistamine product.In a comparative pharmacokinetic study, Gelteq’s formulation demonstrated a 38–45% increase in systemic exposure and absorption (AUC) and markedly higher peak concentrations (Cmax), while maintaining a comparable time to peak plasma concentration (Tmax). The results of the study show Gelteq’s gel-based delivery technology can significantly enhance oral bioavailability of the drug, in addition to the broad benefits of the technology in solving drug delivery, swallowing and patient compliance issues.“These results represent a major technical and commercial milestone for Gelteq,” said Nathan Givoni, CEO of Gelteq. “A 38–45% improvement in bioavailability is transformative and validates our platform’s ability to meaningfully enhance the performance of established drugs. These results also position Gelteq to pursue a much broader portfolio of pharmaceutical opportunities where similar outcomes can be achieved via our proprietary gel-based delivery technology.”Importantly, the findings extend beyond the specific antihistamine evaluated in the study. Because the test compound is water-soluble, the demonstrated bioavailability improvement provides a strong foundation for applying Gelteq’s platform across a range of other water-soluble drug classes, significantly broadening the Company’s commercial scope.“These results support our strategy of partnering and developing gel-based formulations across a wide range of therapeutically relevant compounds,” Mr. Givoni added. “We believe this opens up opportunities well beyond the antihistamine market, and into much larger drug categories where improved absorption, ease of administration, and patient-friendly formats can create immediate value.”The Company anticipates using these results to further pursue an FDA approval pathway for an antihistamine product and to increase engagement with potential pharmaceutical partners interested in next-generation drug delivery formats.About Gelteq Ltd.Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company dedicated to developing and commercialising gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing. For more information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=zwQiCLySeIAI02hCDTtMJ_XwQ_DcYTFsS5dk4fG-CiMroF8kyo2sZhCD9MSZa2b5cXadAURM7xgdw4qzJ-iQVw==">www.gelteq.com</a>.Gelteq Contact: Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 mkreps@darrowir.comForward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 17, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/NewsRoom/AttachmentNg/178e1a9c-f21e-4691-add7-b1398d96f7a6"><img style="height:auto;" src="https://ml.globenewswire.com/media/178e1a9c-f21e-4691-add7-b1398d96f7a6/small/gelteq-jpg.jpg" alt="Primary Logo" width="150" height="22"></a>Source: Gelteq LimitedReleased November 24, 2025Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform

Findings Anticipated to Unlock Broad New Commercial Opportunities Across Water-Soluble Drug Classes

Collaboration with Monash University to Address a Large Pharmaceutical OpportunityMELBOURNE, Australia, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced it has started a preclinical animal trial evaluating its proprietary formulation technology for oily and poorly soluble drugs. Gelteq will conduct the study with Monash University Institute of Pharmaceutical Science, a recognised leader in pharmaceutical development and contract research.“Effective oral delivery of oily and poorly soluble drugs represents one of the biggest challenges in drug development and commercialisation,” said Nathan Givoni, CEO of Gelteq. “More than 40% of marketed drugs and up to 90% of discovery candidates suffer from low solubility and variable bioavailability, leading to higher dosing, greater side effect risk, and inconsistent patient outcomes. By leveraging Gelteq’s formulation expertise, we aim to unlock the full potential of oily and poorly soluble drugs, revive shelved molecules and create new value for global pharmaceutical partners.”Pharmaceutical companies invest more than USD $4 billion annually in technologies to improve delivery of oily and poorly soluble drugs (1), including solubility-enhancement excipients, lipid-based formulations and lipid nanoparticles with strong projected growth through 2030 (1,2,3). However, there are increasing concerns that emulsifiers in lipid-based drug delivery can disrupt the gut microbiota and compromise gastrointestinal health so it is important to reduce reliance on such additives to enable safer and more effective delivery of oily or poorly soluble drugs (4).Should Gelteq be able to demonstrate through the trial its ability to work successfully with oily or poorly soluble drugs, Gelteq would seek to assist potential clients with a portfolio of oily and poorly soluble drugs via the following commercial options:<ul><li>Pipeline salvage – reviving promising drug molecules previously abandoned due to solubility and bioavailability issues.</li><li>Lifecycle extension – reformulating existing drugs to provide new patent protection and exclusivity.</li><li>Improved adherence – the potential to reduce API dose size and food-effect dependence, which has the potential for fewer side effects and more consistent patient outcomes. &nbsp;</li></ul>“This preclinical trial represents an important step to demonstrate Gelteq’s ability to transform a major and unmet need across the pharmaceutical industry,” added Mr. Givoni.About Gelteq Ltd.Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company dedicated to developing and commercialising gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing. For more information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=ghc_1cWoQ7sWNEuiP3q4wXp-cnAkRdboWapHgg7qjmyTu6nJhlr3H4qbDL5WPFwavYBQCoaTm1O2DDRtS1C04IAcFih3V5k60HlIe3IPZ8CHWlhgcgVmpE3-ZVdOF5qy">www.gelteq.com</a>.Gelteq Contact: Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 mkreps@darrowir.comForward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the&nbsp;meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than&nbsp;statements of historical fact, contained herein are forward-looking statements. Forward-looking&nbsp;statements involve known and unknown risks, uncertainties, and other factors that may cause actual&nbsp;results to differ materially from those expressed or implied in such statements. For a discussion of&nbsp;these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange&nbsp;Commission (“SEC”), including its Annual Report on Form 20-F filed on November 15, 2024 and its&nbsp;Registration Statement on Form F-1 initially filed with the SEC on July 1, 2025. Gelteq undertakes no&nbsp;obligation to update any forward-looking statements to reflect events or circumstances after the&nbsp;date hereof.References<ol><li>360iResearch. (2024). Solubility enhancement excipients market: Global forecast 2025–2032 (Report ID: 5675273). Research and Markets.</li><li>Allied Market Research. (2025). Targeted liposomes drug delivery market: Global opportunity analysis and industry forecast, 2023–2032 (Report ID: A12661).</li><li>Grand View Research. (2025). Lipid nanoparticle market, 2025–2030 (Report ID: GVR-4-68040-547-5).</li><li>Subramaniam, S., Elz, A., Wignall, A., Kamath, S., Ariaee, A., Hunter, A., et al. (2023). Self-emulsifying drug delivery systems (SEDDS) disrupt the gut microbiota and trigger an intestinal inflammatory response in rats. International Journal of Pharmaceutics, 648, 123614.</li></ol><a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/NewsRoom/AttachmentNg/178e1a9c-f21e-4691-add7-b1398d96f7a6"><img style="height:auto;" src="https://ml.globenewswire.com/media/178e1a9c-f21e-4691-add7-b1398d96f7a6/small/gelteq-jpg.jpg" alt="Primary Logo" width="150" height="22"></a>Source: Gelteq LimitedReleased October 23, 2025Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform

Gelteq began a preclinical trial with Monash University to test its gel technology for improving the oral delivery of oily and poorly soluble drugs.

MELBOURNE, Australia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced it has entered into a Product Development and Profit Share Agreement (the “Agreement”), with Melbourne Health (“Melbourne Health”), operator of The Royal Melbourne Hospital and one of Australia’s top public health services with extensive research capabilities.Under the Agreement, Gelteq and Melbourne Health will develop new products incorporating high-amylose maize starch butyrylated, or HAMSB, a unique compound with the potential to reduce bowel polyp growth which could lower the risk of bowel cancer.HAMSB, a form of acylated starch, has been the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=IiFWhog97FjccjZ25TKKgFPo-I7ttXwKY_2G30wBFiI1FFeNQIbI6PaoGcva4LF1JrsozHeD3VjEpHhfU6IgwI3Rs661b5NfFSsavEMx1SCwpfUM4sgFzQjT3yF67iLbEvR038aD87AjHKZ_9tADUqc_HSMzAGfIP9zEv5BqRmuQg-oOc3HQwiQ60jc87YIGOroqO5SMTlPqFhWNBfuQWMjgB2AaDK9Y9n-pgYBSMvE=">focus of significant research</a>conducted by the Melbourne Health and the Commonwealth Scientific and Industrial Research Organisation (“CSIRO”). A recent study has demonstrated HAMSB’s significant effects on polyp initiation pointing towards an alternative and innovative approach in colorectal health management. The results of this Australian study, originally presented as part of <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=BzYZvLBS_-m4qIcQYZVmI22QfIAj7U8gpq-Q10AOOXkcmwYWBJQcWTGbFHloHS2FpZ4U144L_w6MuUmuQI4P5zjZSbUfO15miWFbtI7lGFA=">Digestive Disease Week</a> 2024, are accessible online <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=OBnVb4ebvbnIXG6wpM1ub6KUUsUvFL4t4fD0aIdt936X0xYpqQcmFMzod3iKO9Mv2vrF7kbWy0kozL0MMSDoEjRaGQISZg-rnd2TEWxcru2-17d-EsDefUMwQAcswTwi0GKDlG0TDJsrKzPoE3n0jwsmZBppBvwEeMMZ0TdSw74Ecu--8RpsMH-Pd7qE1f_1">here</a>.Melbourne Health and Gelteq will leverage Gelteq’s proprietary gel-based oral delivery platform to develop and formulate a ready-to-consume HAMSB product designed to enhance patient compliance and efficacy in preventive health applications.“This collaboration with Melbourne Health marks a pivotal step in translating cutting-edge clinical research into a potentially commercially viable product that could meaningfully reduce the risk of bowel cancer,” said Nathan Givoni, CEO of Gelteq. “By combining Melbourne Health’s expertise and robust research foundation with Gelteq’s innovative gel technology, we seek to deliver meaningful health benefits in a convenient, user-friendly format.”Many bowel cancers originate from polyps, which underscores the need for new approaches to bowel polyp prevention and reduction in addition to good colorectal health management and regular screenings. Although bowel cancers remains highly treatable when detected early, bowel cancer is the fourth most common cancer diagnosis in Australia, affecting up to 1 in 20 people by age 85, according to <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=kVNWakYmuOB9FxBeBcO22F1M-jt3fZ-3DeZ44jEJODMSLQEK-GdlX4xOcVCHTi4l7Y1p8i1_XcrjDqncqoB0sklkXMseZN4I5-e92saEIOY9Y2O7JH2p8SlTDgjWlzfYSfnXL8m5JBn6qvLa_nhOoZY2lP4FsBVUBMMZyJHauNw=">Cancer Council</a>, Australia’s leading cancer charity,. In the United States, the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=7sQkE8FksrEynxYfi6FtdjagxOUsiI4JaS81NsSs8nb-J3Pn5IIOuSi0Kg0SBOs6UaQS2FZT8Ovq4NWXi38baFDjvkjqwElzJg-ca2XqD3t6p-_CY2vzirW8gWUx8Gm2x_ntw-WwOCb4Uu8bxZfLSA==">Colorectal Cancer Alliance</a> identifies colorectal cancers as the second leading cause of cancer deaths in the United States.Under the Agreement, Gelteq and Melbourne Health have established a profit-sharing model that will provide Melbourne Health with a share of net profits from future product commercialisation. The profit-sharing model recognizes Melbourne Health’s pivotal role in contributing to research and fostering collaborative innovation in healthcare.Gelteq’s research facility in Clayton, Victoria, where the Company is responsible for all manufacturing, marketing, and commercialisation activities, will conduct the product development program.About Gelteq Ltd.Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company dedicated to developing and commercialising gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing. For more information, visit&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=mfrxHW9eac_dFvbDW-ysl4Xt4s2qratQy9AVVIAkFwLIxD_lP2cFUYjm6Rextsbw7CgIBl8k4GCPWDw6HhcsOQ==">www.gelteq.com</a>.Gelteq Contact:Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 mkreps@darrowir.comForward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission (“SEC”), including its Annual Report on Form 20-F filed on November 15, 2024 and its Registration Statement on Form F-1 initially filed with the SEC on July 1, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/NewsRoom/AttachmentNg/178e1a9c-f21e-4691-add7-b1398d96f7a6"><img style="height:auto;" src="https://ml.globenewswire.com/media/178e1a9c-f21e-4691-add7-b1398d96f7a6/small/gelteq-jpg.jpg" alt="Primary Logo" width="150" height="22"></a>Source: Gelteq LimitedReleased October 9, 2025Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq Announces New Product Development Agreement with Melbourne Health for Novel Bowel Polyp Growth Reduction Compound

Gelteq has partnered with Melbourne Health to develop a novel, gel-based oral product using HAMSB to potentially reduce bowel polyps and lower the risk of bowel cancer.

MELBOURNE, Australia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company,” NASDAQ: GELS), a clinical and science-based developer of gel-based oral delivery solutions, welcomes the recently&nbsp;announced product launches of <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=m_DdCQTpOIEkyMW6a_LTNu80nA-fvUjxL3WRLmnGS69pjlEjzE7uri5nWw8o-jN5ufZ7dm_TD-F_EgPyk3wUaQdHmXCqk3fv6wOqrJUixIc=">Healthy Extracts, Inc.</a>(“Healthy Extracts,” OTCQB: HYEX), whose products apply Gelteq’s proprietary gel technology, <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=jVTfFSVxnjolcQWdJUHguUDpIFQsKOiqOBXBpcPqudxVaqM7qCSY6qp7CcK5vPQJFCo7hIArwK5VrglasVoSV6fkl1MhXuC0Z8-hE_a4204rIsukKFHSs6N8s2fDFE3nNeNsvZBeBaVYTKiPqDW3LCAe7Pbvi1Ykp2jwWuGNhVBrcGVtaGDqvv_XCRaSX9V2pmGKXGiBfHNkQZ7JeBNpdl8KBByCsg5_bPZoMX49Lldu2oACh7Wdw4rKa5E1y6JJfaWZzk6107bQ3c5yeCotSV3KY6uN9ysKWvWsic3iFkfv13xMn1h_G_ovXuIFktP5">into the U.S. nutraceutical market</a>.The Healthy Extracts products are the first to reach Gelteq’s U.S. warehousing facility using Gelteq’s delivery platform, an important milestone that marks Gelteq’s transition from R&amp;D to active commercialization in the U.S. This development highlights both the growth potential of Gelteq’s technology in large-scale wellness markets in the U.S. and its ability to meet consumer demand for innovative, convenient, and clinically-informed formats.“We are pleased to see Gelteq’s technology expand into the U.S. market through our collaboration with Healthy Extracts,” said Nathan Givoni, CEO of Gelteq. “Healthy Extract’s launch demonstrates how our gels can be adapted to create differentiated, consumer-friendly solutions, while paving the way for additional products and partnerships across the U.S. market.”The collaboration with Healthy Extracts, first announced earlier this year, began with warehousing and fulfilment arrangements which laid the foundation for Gelteq's entry into the U.S. market. With this launch, the partnership with Healthy Extract has advanced into active sales and distribution, underscoring the growing momentum behind Gelteq’s gel delivery system and the potential for additional partnership opportunities in the U.S.About Gelteq Ltd.Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company dedicated to developing and commercialising gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing. For more information, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=CzDiesrgFr3dtr9zZyTAj8WQwqMRYCl9wExZjU5Avfu8KSGuGlzGWsggV7F94VXP7gCRfpAAoHjXJ2X5fMFejCkzv8bsd_YZymXULDOahWLGd0vI2gPkcqhcg17_0Yfr">www.gelteq.com</a>.Gelteq Contact: Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 mkreps@darrowir.comForward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission (“SEC”), including its Annual Report on Form 20-F filed on November 15, 2024 and its Registration Statement on Form F-1 initially filed with the SEC on July 1, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq Technology Powers U.S. Product Launches of its Nutraceutical Products for Partner

Gelteq has entered the U.S. market and transitioned from research and development to commercialization with the launch of gel-based products by its partner, Healthy Extracts.

MELBOURNE, Australia, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced plans to commence a preclinical bioequivalence study in September 2025 to evaluate its novel gel-based formulation of a widely used antihistamine for allergy treatment. The study will be conducted by Adgyl Lifesciences (a partner of Eurofins Advinus), a leader in preclinical contract research services.If preclinical results are successful, Gelteq anticipates advancing to human clinical trials targeting U.S. Food and Drug Administration (FDA) approval via the 505(b)(2) regulatory pathway.“Our gel-based delivery platform is expected to transform traditional pharmaceutical products currently available on the market, especially where patient compliance and dosage control are critical,” said Nathan Givoni, CEO of Gelteq. “By applying our technology to a well-established antihistamine, we see a significant opportunity to capture value in the allergy market, where patient-friendly formats and flexible dosing remain unmet needs.”Allergic conditions affect over 50 million people annually in the United States alone (1). The global antihistamine market was valued at approximately USD $9 billion in 2023 growing at a 6% CAGR, projected to reach over USD $12 billion by 2028 (2). Demand spans paediatric, adult, and increasingly, animal health (3), reflecting the diverse applications for antihistamine therapies.Gelteq’s proprietary gel formulations aim to address key limitations of traditional tablets and syrups, including palatability challenges for children, swallowing difficulties for elderly patients, and precise dosing needs in veterinary medicine (3).“Our innovative gel technology offers potential advantages in taste masking, ease of administration, and flexible dosing,” added Mr. Givoni. “These attributes are particularly relevant in paediatrics and veterinary care where delivering effective allergy treatments can be challenging.”About Gelteq Ltd.Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company dedicated to developing and commercialising gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing. For more information, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=O19-A9YeYzwuzvF6uGAfqtDG5RRZjNh8mE7N1rM43qWuYEEherjJSFHi9Ncl812p3GbOQCQNBsWSS797RiLzww==">www.gelteq.com</a>.Gelteq Contact:Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 mkreps@darrowir.comForward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 15, 2024. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.References<ol style="list-style-type:decimal;"><li>American College of Allergy, Asthma &amp; Immunology. (2023). Allergy facts. American College of Allergy, Asthma &amp; Immunology. <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=BNccLheL2BHDT5LVrxyDH2GA_gxthxCKK2am7PO7NqJTQcy2YC8ka5Kcte6IYk-_rkMMxzQMPvg2HqpjhYc9h72dvj8f127hx_V37sDA6KM=">https://acaai.org/allergies/</a></li><li>Grand View Research. (2024, March). Antihistamine market size, share &amp; trends analysis report. Grand View Research. <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=BNccLheL2BHDT5LVrxyDH8PA2iF4YPFOJnnXWrzLVPWX86_Wv7NSRcESK7JjTDN70jZpuPqpdsx_TBhsE_ulMsIgBJxpUBj13R4ETgeMYf2vk4jcPQISkwfsg1zYJE63DSmPuNhJhhBdTdUIzZKfJ9KWwDWruOryJwg7nm8RSHcuoR3YA-Wn6p7-YvPDoF3fCQ0atmiqwvReNLCbM7tPS-i_fie6yjzGM21gSt4TLW8X8McYSh-w8FfqP1mvol0z">https://www.grandviewresearch.com/industry-analysis/antihistamine-market</a></li><li>MarketsandMarkets. (2023, November). Veterinary dermatology drugs market by product, animal type, route of administration, end user – Global forecast to 2028. MarketsandMarkets. <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=BNccLheL2BHDT5LVrxyDH2Y1c895h1WrE2q8doDlYL1Ih6-5ysKO0PaJX-tphZJJStCjpjTLUUpMpUV9mhXVNK5FNLLa-zQHGWQ_B54syEdWd1IfeFXhWlqU7sjNYhquPgonhJoiVzv-ITdIV85I8IM23Z11Bfhxpq1a1_GLzd4eL402y-zBojIsxjwBqtdEDB_GkSWA1jEq6FQ_hAJ20teMk3pmiCXapAHCSC97v8t-RGifPW7uovJqJo2C_PfBuJyCntgc2WPWifTl4gP1FwrDiGwagc9NPUwLVWidNu47-s8qC0JOu9g0EzXQHXrvMq8x9Bg8Kt0gb5gX1HJARQ==">https://www.marketsandmarkets.com/Market-Reports/veterinary-dermatology-drugs-market-177021512.html</a></li></ol>Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market

Study to Support Potential FDA Approval via 505(b)(2) Pathway

Jul. 17, 2025 8:30 AM ET<a target="_blank" rel="noopener noreferrer nofollow" href="https://seekingalpha.com/symbol/GELS#source=section%3Amain_content%7Csection_asset%3Ameta%7Cfirst_level_url%3Aarticle%7Csymbol%3AGELS">Gelteq Limited (GELS)</a>GlobeNewswireNEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (<a target="_blank" rel="noopener noreferrer nofollow" href="https://seekingalpha.com/symbol/GELS#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link">GELS</a>) (“Gelteq” or the “Company”), a clinical and science-based company focused on developing and commercializing white label ingestible gel-based solutions for prescription drugs, nutraceuticals, pet care, sports and other products, today announced it has entered into a memorandum of understanding with IDT Australia (ASX: IDT) for a dedicated, locally based manufacturing facility to support the development and scale up of its gel-based products across diverse global pharmaceutical, nutraceutical and animal health markets.IDT is internationally recognized for its expertise in pharmaceutical projects and contract manufacturing services developed across more than 50 years of operation and over 60 market-based drugs. The company specializes in pharmaceutical product development and cGMP manufacture including high containment, high potency manufacture of Active Pharmaceutical Ingredients (API), oral and sterile dose FDA and TGA approved laboratory testing, and clinical packaging. IDT is also at the forefront of developing and manufacturing advanced therapies including mRNA and Antibody Drug Conjugates (ADCs).“Partnering with IDT to establish a locally-based, purpose-built manufacturing facility strategically positions Gelteq to accelerate and scale our products for the global nutraceutical, pharmaceutical and animal health markets,” said Nathan Givoni, CEO of Gelteq. “IDT not only brings proven development, manufacturing and regulatory expertise to support our goals, but also a unique knowledge base to speed up the development of new products targeting these markets.”Paul McDonald, CEO of IDT Australia, commented: “We are excited to combine IDT’s proven development and manufacturing capabilities with Gelteq’s innovative delivery system for wellness and therapeutic products. Gelteq’s proprietary gel technologies offer distinct benefits in both delivery and combination therapy opportunities needed to improve care and dosing compliance across many end markets.”Highlights of the Agreement:<ul><li>Facilities and Equipment required for the manufacture of Gelteq products, in a dedicated building and purpose-built facility, trained staff and operational support.</li><li>Compliance and Certification necessary for products in the therapeutic, veterinary and nutraceutical markets across various product presentations, including regulatory requirements, permits, and licenses from the APVMA, FDA, and TGA.</li><li>Rapid Scale Up Capability to integrate additional manufacturing space and equipment to support growth. &nbsp;</li></ul>About Gelteq Ltd. Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, sports and other products. Gelteq advances and commercializes its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition.The Company’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=00K18qA_R_h14eUsBeqQWCgMgMmxuWb3BtGKz6ILL5yQ1_R8YgVe3aEx_L8wLAZZPAeltknTuVaIh-pb4Kiy8g==">www.gelteq.com</a> and our SportsGel brand website <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=-p3-I0mUlJnWPMf-dUcDiLZEc5RjeyAm-S2zUBjuzZqsz6gVrldwGFhUq191BEReZ8bR_Byc31VTexJpTREpLHRAjbEauYCyxSObvUI2IKY=">www.sportsgel.com</a>.Gelteq Contact:&nbsp; Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=lXdnLIhrjHSBfmEF8ctV8ZAmFeM-Ds7RVQBML108A473uXIgHycUxnGOSxVLrfBanFWPU-bmwMn1gK9Fn6lO2U8ADzIpjoyqaUQJQBtbSJM=">mkreps@darrowir.com</a>Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Gelteq’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and fulfilment of current and future orders relating to Gelteq’s products, the success of new programs, the ability to implement a new strategic plan and the success of a new strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gelteq in general, see the risk factors in its Annual Report on 20-F filed on November 15, 2024. All such forward-looking statements speak only as of the date they are made, and Gelteq undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.Source: Gelteq Limited 2025 GlobeNewswire, Inc.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq Announces Agreement with IDT Australia to Secure Dedicated New Product Development and Manufacturing Facilities

https://seekingalpha.com/pr/20169476-gelteq-announces-agreement-with-idt-australia-to-secure-dedicated-new-product-development-and

Shares of Gelteq (GELS) soared 71% on Tuesday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.gelteq.com/news-events/press-releases/detail/103/gelteq-expands-u-s-operations-with-healthy-extracts-inc">announced</a> an exclusive logistics and distribution agreement with Healthy Extracts Inc. in a bid to expand operations in North America.The agreement names Healthy Extracts as Gelteq’s exclusive North American storage, shipping, and fulfillment partner. Healthy Extracts is a publicly traded company focused on plant-based health supplements.Gelteq expects to rapidly scale the distribution of its white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, sports, and other products across the United States and Canada, while significantly reducing costs and boosting revenue potential.Under the new agreement, Healthy Extracts will manage all product receiving, secure warehousing, inventory, and order fulfillment from its Henderson, Nevada, facility. The collaboration is expected to reduce fulfillment costs and unlock high-margin revenue opportunities for both Gelteq and Healthy Extracts.“We believe this is a scalable, profitable model for both companies and our shareholders,” said Duke Pitts, President of Healthy Extracts.The initial products to be received under this new agreement are on track for market distribution by the third quarter (Q3) of 2025.On Stocktwits, retail sentiment around Gelteq jumped from ‘extremely bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_10_at_1_19_18_PM_png_58ec493774.webp" alt="GELS's Sentiment Meter and Message Volume as of 1:15 p.m. ET on June 10, 2025 | Source: Stocktwits" width="628" height="64"><figcaption>GELS's Sentiment Meter and Message Volume as of 1:15 p.m. ET on June 10, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/GELS">GELS stock</a> is up by about 22% this year and down by about 1% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/us-fda-places-clinical-hold-on-gilead-trials-of-two-investigational-hiv-treatments/chl7qNLRbzY">US FDA Places Clinical Hold On Gilead Trials Of Two Investigational HIV Treatments: Retail’s On The Fence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Gelteq Stock Soars On Deal With Healthy Extracts For Product Distribution In North America: Retail Chatter Explodes

The agreement names Healthy Extracts as Gelteq’s exclusive North American storage, shipping, and fulfillment partner.

Equity

Gelteq Ltd. operates as a biotechnology company. It focuses on the development and commercialization of white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products. The firm also offers edible gels. The company was founded by Nathan J. Givoni and Simon H. Szewach on October 15, 2018 and is headquartered in Melbourne, Australia.

GELS
Gelteq Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest GELS News

GELSGelteq Ltd.